€2 Billion Investment Revolutionizes DHL’s Global Healthcare Logistics Network

€2 Billion Investment Revolutionizes DHL’s Global Healthcare Logistics Network

(IN BRIEF) DHL Group has announced a €2 billion strategic investment over the next five years to enhance its logistics operations in the life sciences and healthcare sectors, aligning with its “Strategy 2030”. The investment is aimed at supporting healthcare customers by expanding DHL’s global logistics infrastructure, with 50% allocated to the Americas, and 25% each to Asia Pacific and EMEA. The initiative will focus on upgrading storage, order fulfillment, distribution, global shipping, and last-mile delivery systems to create resilient and scalable supply chains. Key investments include developing GPD-certified Pharma Hubs for multi-temperature shipments, expanding cold chain capacities, deploying new temperature-controlled vehicles, and advancing both passive and active packaging solutions. As demand increases in areas such as clinical trials, biopharma, and cell and gene therapies, DHL will also invest in specialized cooling infrastructure and IT systems to ensure complete end-to-end visibility and regulatory compliance. Rebranded under DHL Health Logistics, the new approach consolidates the Group’s expertise in life sciences and healthcare logistics, promising an integrated and agile service for pharmaceutical, biopharma, and medical sectors. With nearly 600 sites worldwide and significant revenue from this sector, DHL’s recent acquisition of CRYOPDP further strengthens its capabilities in specialized healthcare logistics.

(PRESS RELEASE) BONN, 7-Apr-2025 — /EuropaWire/ — DHL Group has unveiled a strategic investment of €2 billion over the next five years aimed at strengthening its logistics capabilities within the life sciences and healthcare sectors. This major investment underpins the Group’s “Strategy 2030” and underscores its dedication to empowering healthcare customers worldwide by enabling them to innovate, expand, and deliver essential patient care more effectively. With half of the funds earmarked for the Americas, and the remainder equally divided between Asia Pacific and EMEA, DHL is set to broaden its global reach and provide integrated, faster, and more reliable logistics solutions.

Central to this initiative is the enhancement of DHL’s infrastructure and technology across all logistics components—from storage, order fulfillment, and distribution to global shipping and last-mile delivery—resulting in more resilient and scalable supply chains. A significant portion of the investment will finance the development of new, cross-divisional GPD-certified Pharma Hubs for multi-temperature shipment lanes, boost cold chain capacity at existing facilities, introduce new temperature-controlled vehicles, and improve both passive and active packaging solutions to secure sustainable delivery.

The investment comes at a time when demand is surging in critical sectors such as clinical trials, biopharma, and cell and gene therapies. DHL is, therefore, prioritizing the establishment of specialized cooling infrastructure capable of handling low and ultra-low temperature ranges, alongside cutting-edge IT systems that offer end-to-end visibility to ensure product integrity and regulatory compliance.

Under its new sector brand, DHL Health Logistics, the Group is unifying its life sciences and healthcare expertise to provide a seamless, comprehensive experience. This consolidation simplifies the management of intricate, cross-border supply chains, delivering agile, connected solutions that exceed traditional service lines. “Similar to DHL Group’s purpose of ‘Connecting people, improving lives’, our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” stated Oscar de Bok, CEO of DHL Supply Chain. He emphasized that the innovative and integrated logistics solutions being developed will ensure that patients globally receive the right treatments at the right time with unwavering confidence.

DHL Group, already a trusted partner in the life sciences and healthcare arena with nearly 600 dedicated sites and over 2.5 million square meters of temperature-controlled storage across approximately 130 countries, is reinforcing its market leadership. The Group’s 2024 revenue in this sector surpassed EUR 5 billion, with an anticipated incremental revenue of another EUR 5 billion by 2030. Additionally, the recent acquisition of CRYOPDP—a leading specialty courier for clinical trials, biopharma, and cell and gene therapies—further bolsters its Pharma Specialized Network, expanding the scope of its comprehensive investment strategy.

DHL Group is the world’s leading logistic company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees, investors and green logistics worldwide. To this end, DHL Group is focusing on accelerating sustainable growth in its profitable core logistics businesses and Group growth initiatives. The Group contributes to the world through sustainable business practices, corporate citizenship, and environmental activities. By the year 2050, DHL Group aims to achieve net-zero emissions logistics.

DHL Group is home to two strong brands: DHL offers a comprehensive range of parcel, express, freight transport, and supply chain management services as well as e-commerce logistics solutions. Deutsche Post is the largest postal service provider in Europe and the market leader in the German mail market. DHL Group employs approximately 602,000 people in over 220 countries and territories
worldwide. The Group generated revenues of approximately 84.2 billion Euros in 2024.

The logistics company for the world.

Media Contact:

Daniel Pohl
Phone: +49 228 182-9944
E-mail: pressestelle@dhl.com

SOURCE: DHL